Chantix-Champix revenue trends
In 2016, Pfizer’s (PFE) Chantix reported revenues of ~$842 million, which represents a ~25% YoY (year-over-year) rise. The company claimed that foreign exchange saw a ~1% negative impact on Chantix’s revenues in 2016.
In the US, the drug witnessed a 40% YoY rise in 2016. Its direct-to-consumer campaigns, increased demand, and the increase in the price of the drug in the US attributed to its revenue growth.
In 1Q17, Chantix generated revenues of ~$239 million, which was ~9% higher YoY and 13% higher on a QoQ (quarter-over-quarter) basis. In 1Q17, US Chantix revenues witnessed a ~12% YoY rise. The growth was primarily driven by the direct-to-consumer marketing strategy and the promotion of its Reduce-to-Quit approach.
Toviaz (fesoterodine fumarate) revenue trends
In 2016, Toviaz reported revenues of ~$258 million, compared with $267 in 2015. In 1Q17, Toviaz generated revenues of ~$63 million, which was ~2% lower YoY and 6% lower QoQ.
Toviaz is indicated for the treatment of individuals with urge urinary incontinence. (To know more about Toviaz, please refer to Market Realist’s Toviaz Expected to Report Stable Revenues in 2016.)
Viagra revenue trends
In 2016, Viagra generated revenues of ~$1.6 billion, which represented a ~8% YoY fall. In 1Q17, Viagra generated revenues of ~$339 million, which was ~14% lower YoY ~11% lower QoQ. The lower market demand and increased rebates on prices attributed to the decline of Viagra revenues in 1Q17.
Pfizer’s Viagra faces stiff competition from Eli Lilly’s (LLY) Cialis, Bayer’s (BAYZF) Levitra and Staxyn, and other generic drug manufacturers’ drugs. Notably, the iShares US Pharmaceuticals ETF (IHE) has ~8.2% of its total portfolio holdings in Pfizer. IHE has ~10.1% and ~6.0% of its total portfolio holdings in Johnson & Johnson (JNJ) and Eli Lilly, respectively.